Tomonobu Koizumi

Tomonobu Koizumi

Auto-generated profile, based on publicly available information

Tomonobu Koizumi

Department of Medicine Nagano Prefectural Kiso Hospital Nagano Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2015 in Respiration
Verified
Journal Article
Closed access
TKTomonobu Koizumi
Tomonobu Koizumi
KTKenji Tsushima
Kenji Tsushima
TTTsuyoshi Tanabe
Tsuyoshi Tanabe
TAToshihiko Agatsuma
Toshihiko Agatsuma
TYToshiki Yokoyama
Toshiki Yokoyama
MYMasanori Yasuo
Masanori Yasuo
Background: Our previous animal and preliminary human studies indicated that bronchoscopy-guided cooled radiofrequency ablation (RFA) for the lung is a safe and feasible procedure without major complications. Objectives: The present study was performed to evaluate the safety, effectiveness and feasibility of computed tomography (CT)-guided bronchoscopy cooled RFA in patients with medically inoperable non-small-cell lung cancer (NSCLC). Methods: Patients with pathologically diagnosed NSCLC, who had no lymph node involvement or distant metastases (T1-2aN0M0) but were not surgical candidates because of comorbidities (e.g. synchronous multiple nodules, advanced age, cardiovascular disease, poor pulmonary function, etc.) were enrolled in the present study. The diagnosis and location between the nearest bronchus and target tumor were made by CT-guided bronchoscopy before the treatment. A total of 28 bronchoscopy-guided cooled RFA procedures were performed in 20 patients. After treatment, serial CT imaging was performed as follow-up. Results: Eleven lesions showed significant reductions in tumor size and 8 lesions showed stability, resulting in a local control rate of 82.6%. The median progression-free survival was 35 months (95% confidence interval: 22-45 months), and the 5-year overall survival was 61.5% (95% confidence interval: 36-87%). Three patients developed an acute ablation-related reaction (fever, chest pain) and required hospitalization but improved with conservative treatment. There were no other adverse events in the present study. Conclusions: CT-guided bronchoscopy cooled RFA is applicable for only highly selected subjects; however, our trial may be an alternative strategy, especially for disease local control in medically inoperable patients with stage I NSCLC.

1 April 2010 in Chest
Verified
Journal Article
Closed access
PDF file
TTTsuyoshi Tanabe
Tsuyoshi Tanabe
TKTomonobu Koizumi
Tomonobu Koizumi
KTKenji Tsushima
Kenji Tsushima
MIMichiko Ito
Michiko Ito
SKShintaro Kanda
Shintaro Kanda
KYKazuo Yoshida
Kazuo Yoshida

3 February 2009 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
AUAtsuhito Ushiki
Atsuhito Ushiki
TKTomonobu Koizumi
Tomonobu Koizumi
NKNobumitsu Kobayashi
Nobumitsu Kobayashi
SKShintarou Kanda
Shintarou Kanda
MYMasanori Yasuo
Masanori Yasuo
JNJun Nakayama
Jun Nakayama
Somatic epidermal growth factor receptor (EGFR) mutations in exons 19 and 21 have been found in non-small cell lung cancer (NSCLC) and are associated with the therapeutic response to gefitinib in patients with advanced NSCLC. We report a case of pleomorphic carcinoma of the lung with different EGFR mutations. Prior to gefitinib treatment, an exon 19 deletion of EGFR mutation was positive in the specimens obtained from pleural effusion and left cervical lymph node, histologically proven to be adenocarcinoma. However, the response to gefitinib was poor and the patient died of progressive disease 4 months after the initiation of gefitinib therapy. Postmortem examination revealed the major histological component to be of the sarcomatoid or pleomorphic type with scant mixed adenocarcinoma, resulting in a histological diagnosis of pleomorphic carcinoma of the lung. Although the adenocarcinomatous tissue was still positive for exon 19 deletion of EGFR mutation alone, sarcomatous components had both the exons 19 deletion and 20 T790M mutation concomitantly, thought to be a gefitinib resistance mutation. Pulmonary pleomorphic carcinoma is a rare NSCLC composed of biphasic and heterogeneous malignant cell populations. The present case suggested that expression of different EGFR mutations is related to the biphasic histological appearance in pulmonary pleomorphic carcinoma.

1 December 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
TAToshihiko Agatsuma
Toshihiko Agatsuma
TKTomonobu Koizumi
Tomonobu Koizumi
SKShintaro Kanda
Shintaro Kanda
MIMichiko Ito
Michiko Ito
KUKazuhisa Urushihata
Kazuhisa Urushihata
KKKeishi Kubo
Keishi Kubo
Introduction: Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma has not yet been established because of its rare occurrence. The purpose of this study was to evaluate the efficacy and tolerability of combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. Methods: A retrospective analysis of 34 patients with untreated and unresectable thymic carcinoma who received chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds between 1996 and 2010 was conducted. Twenty-nine patients were treated with a combination of cisplatin (50 mg/m2) and doxorubicin (40 mg/m2) on day 1, vincristine (0.6 mg/m2) on day 3, and cyclophosphamide (700 mg/m2) on day 4. Five patients were treated with carboplatin (area under the curve of 3.0 minutes · mg/ml) instead of cisplatin. Results: The responses of all 34 patients to the current regimen were assessed. The median number of treatment cycles for the present chemotherapy was 4. The overall response rate and disease control rate were 50.0% and 88.2%, respectively. The median survival was 21.3 months (95% confidence interval [CI], 15.0–37.2 months), and the 1-year and 3-year survival rates were 72.7% (95% CI, 56.8–88.6%) and 34.4% (95% CI, 16.2–52.6%), respectively. The most common adverse event was leukopenia/neutropenia, and nonhematological toxicities were mild. Conclusions: Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds is an effective and well-tolerated treatment for unresectable advanced thymic carcinoma.

18 October 2018 in Blood Advances
Verified
Journal Article
Closed access
PDF file
TKToru Kawakami
Toru Kawakami
NSNodoka Sekiguchi
Nodoka Sekiguchi
JKJun Kobayashi
Jun Kobayashi
TITatsuya Imi
Tatsuya Imi
KMKazuyuki Matsuda
Kazuyuki Matsuda
FIFumihiro Ishida
Fumihiro Ishida
Dysregulation of T-cell–mediated immunity is responsible for acquired pure red cell aplasia (PRCA). Although STAT3 mutations are frequently detected in patients with T-cell large granular lymphocytic leukemia (T-LGLL), which is often complicated by PRCA and which is also reported to be associated with acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS), whether STAT3-mutated T cells are involved in the pathophysiology of PRCA and other types of bone marrow failure remains unknown. We performed STAT3 mutation analyses of the peripheral blood mononuclear cells from PRCA patients (n = 42), AA (n = 54), AA–paroxysmal nocturnal hemoglobinuria (AA-PNH; n = 7), and MDS (n = 21) using an allele-specific polymerase chain reaction and amplicon sequencing. STAT3 mutations were not detected in any of the 82 patients with AA/PNH/MDS but were detected in 43% of the 42 PRCA patients. In all 7 STAT3-mutation–positive patients who were studied, the STAT3 mutations were restricted to sorted CD8+ T cells. The prevalence of STAT3 mutation in idiopathic, thymoma-associated, autoimmune disorder–associated, and T-LGLL–associated PRCA was 33% (5 of 15), 29% (2 of 7), 20% (1 of 5), and 77% (10 of 13), respectively. The STAT3-mutation–positive patients were younger (median age, 63 vs 73 years; P= .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; P= .0092) in comparison with STAT3-mutation–negative patients. The data suggest that STAT3-mutated CD8+ T cells may be closely involved in the selective inhibition of erythroid progenitors in PRCA patients. Key Points Somatic STAT3 mutations were frequently found in PRCA with or without T-LGLL. STAT3 mutation–positive PRCA patients were less responsive to cyclosporine treatment than mutation-negative patients. Visual Abstract

19 September 2017 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
TITakashi Ichiyama
Takashi Ichiyama
DGDaisuke Gomi
Daisuke Gomi
TFToshirou Fukushima
Toshirou Fukushima
TKTakashi Kobayashi
Takashi Kobayashi
NSNodoka Sekiguchi
Nodoka Sekiguchi
YHYoshihisa Hama
Yoshihisa Hama
A 58‑year‑old woman with a histologically confirmed diagnosis of vulvar extramammary Paget's disease (EMPD) was referred to our hospital due to locally advanced and relapsed EMPD. The patient had undergone surgical resection three times for relapsed vulvar EMPD over a period of 12 years, but developed locally advanced and unresectable EMPD. As pathological examination indicated that the lesion was positive for human epidermal growth factor receptor 2 (HER2) on immunohistochemical staining, the patient was treated with trastuzumab plus paclitaxel. The primary tumor mass and lymph node metastasis regressed successfully with combined trastuzumab and paclitaxel therapy, and the disease has been stable for >2 years after the initiation of treatment. These observations suggest that HER2 status must be determined in patients with advanced and/or metastatic extramammary Paget's disease and therapy with HER2 inhibitors should be considered as an option for the treatment of HER2‑positive EMPD.